Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) Shares Outstanding (Diluted Average) (2020 - 2023)

Alx Oncology Holdings' Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $41.0 million for Q3 2023.

  • For Q3 2023, Shares Outstanding (Diluted Average) rose 0.53% year-over-year to $41.0 million; the TTM value through Sep 2023 reached $41.0 million, up 0.53%, while the annual FY2022 figure was $40.7 million, 0.97% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2023 was $41.0 million at Alx Oncology Holdings, roughly flat from $40.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $41.0 million in Q3 2023 and bottomed at $18.5 million in Q4 2020.
  • The 4-year median for Shares Outstanding (Diluted Average) is $40.7 million (2022), against an average of $38.6 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) soared 118.05% in 2021 before it rose 0.45% in 2023.
  • A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $18.5 million in 2020, then soared by 118.05% to $40.3 million in 2021, then grew by 0.97% to $40.7 million in 2022, then increased by 0.65% to $41.0 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Shares Outstanding (Diluted Average) are $41.0 million (Q3 2023), $40.9 million (Q2 2023), and $40.9 million (Q1 2023).